TY - JOUR
T1 - Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children's Hospital in New York City
T2 - Patient Characteristics and an Institutional Protocol for Evaluation, Management, and Follow-Up
AU - Jonat, Brian
AU - Gorelik, Mark
AU - Boneparth, Alexis
AU - Geneslaw, Andrew S.
AU - Zachariah, Philip
AU - Shah, Amee
AU - Broglie, Larisa
AU - Duran, Juan
AU - Morel, Kimberly D.
AU - Zorrilla, Maria
AU - Svoboda, Leanne
AU - Johnson, Candace
AU - Cheng, Jennifer
AU - Garzon, Maria C.
AU - Silver, Wendy G.
AU - Gross Margolis, Kara
AU - Neunert, Cindy
AU - Lytrivi, Irene
AU - Milner, Joshua
AU - Kernie, Steven G.
AU - Cheung, Eva W.
AU - Margolis, Kara
N1 - Funding Information:
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/pccmjournal). Drs. Jonat, Zachariah, Morel, Zorilla, Svoboda, Garzon, Neunert, Kernie, and Cheung disclosed off-label product use of anakinra, methylprednisolone, IV immunoglobulin, low-molecular-weight heparin, and aspirin for treatment of a novel syndrome deemed multisystem inflammatory syndrome in children. Dr. Margolis’ institution received funding from the National Institutes of Health and the Department of Defense, and she received funding from Takeda. Dr. Neunert received funding from Janssen and Sanofi-Genzyme. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Objectives: The disease caused by severe acute respiratory syndrome coronavirus 2, known as coronavirus disease 2019, has resulted in a global pandemic. Reports are emerging of a new severe hyperinflammatory syndrome related to coronavirus disease 2019 in children and adolescents. The Centers for Disease Control and Prevention has designated this disease multisystem inflammatory syndrome in children. Our objective was to develop a clinical inpatient protocol for the evaluation, management, and follow-up of patients with this syndrome. Data Sources: The protocol was developed by a multidisciplinary team based on relevant literature related to coronavirus disease 2019, multisystem inflammatory syndrome in children, and related inflammatory syndromes, as well as our experience caring for children with multisystem inflammatory syndrome in children. Data were obtained on patients with multisystem inflammatory syndrome in children at our institution from the pre-protocol and post-protocol periods. Data Synthesis: Our protocol was developed in order to identify cases of multisystem inflammatory syndrome in children with high sensitivity, stratify risk to guide treatment, recognize co-infectious or co-inflammatory processes, mitigate coronary artery abnormalities, and manage hyperinflammatory shock. Key elements of evaluation include case identification using broad clinical characteristics and comprehensive laboratory and imaging investigations. Treatment centers around glucocorticoids and IV immunoglobulin with biologic immunomodulators as adjuncts. Multidisciplinary follow-up after discharge is indicated to manage continued outpatient therapy and evaluate for disease sequelae. In nearly 2 months, we admitted 54 patients with multisystem inflammatory syndrome in children, all of whom survived without the need for invasive ventilatory or mechanical circulatory support. After institution of this protocol, patients received earlier treatment and had shorter lengths of hospital stay. Conclusions: This report provides guidance to clinicians on evaluation, management, and follow-up of patients with a novel hyperinflammatory syndrome related to coronavirus disease 2019 known as multisystem inflammatory syndrome in children. It is based on the relevant literature and our experience. Instituting such a protocol during a global pandemic is feasible and is associated with patients receiving treatment and returning home more quickly.
AB - Objectives: The disease caused by severe acute respiratory syndrome coronavirus 2, known as coronavirus disease 2019, has resulted in a global pandemic. Reports are emerging of a new severe hyperinflammatory syndrome related to coronavirus disease 2019 in children and adolescents. The Centers for Disease Control and Prevention has designated this disease multisystem inflammatory syndrome in children. Our objective was to develop a clinical inpatient protocol for the evaluation, management, and follow-up of patients with this syndrome. Data Sources: The protocol was developed by a multidisciplinary team based on relevant literature related to coronavirus disease 2019, multisystem inflammatory syndrome in children, and related inflammatory syndromes, as well as our experience caring for children with multisystem inflammatory syndrome in children. Data were obtained on patients with multisystem inflammatory syndrome in children at our institution from the pre-protocol and post-protocol periods. Data Synthesis: Our protocol was developed in order to identify cases of multisystem inflammatory syndrome in children with high sensitivity, stratify risk to guide treatment, recognize co-infectious or co-inflammatory processes, mitigate coronary artery abnormalities, and manage hyperinflammatory shock. Key elements of evaluation include case identification using broad clinical characteristics and comprehensive laboratory and imaging investigations. Treatment centers around glucocorticoids and IV immunoglobulin with biologic immunomodulators as adjuncts. Multidisciplinary follow-up after discharge is indicated to manage continued outpatient therapy and evaluate for disease sequelae. In nearly 2 months, we admitted 54 patients with multisystem inflammatory syndrome in children, all of whom survived without the need for invasive ventilatory or mechanical circulatory support. After institution of this protocol, patients received earlier treatment and had shorter lengths of hospital stay. Conclusions: This report provides guidance to clinicians on evaluation, management, and follow-up of patients with a novel hyperinflammatory syndrome related to coronavirus disease 2019 known as multisystem inflammatory syndrome in children. It is based on the relevant literature and our experience. Instituting such a protocol during a global pandemic is feasible and is associated with patients receiving treatment and returning home more quickly.
KW - clinical protocols
KW - coronavirus disease 2019
KW - coronavirus disease 2019 related
KW - critical care
KW - pediatric multisystem inflammatory disease
KW - pediatrics
KW - severe acute respiratory syndrome coronavirus 2
UR - http://www.scopus.com/inward/record.url?scp=85097171137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097171137&partnerID=8YFLogxK
U2 - 10.1097/PCC.0000000000002598
DO - 10.1097/PCC.0000000000002598
M3 - Article
C2 - 33003176
AN - SCOPUS:85097171137
SN - 1529-7535
VL - 22
SP - E178-E191
JO - Pediatric Critical Care Medicine
JF - Pediatric Critical Care Medicine
IS - 3
ER -